198 related articles for article (PubMed ID: 19811659)
41. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
42. Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation.
Marko J; Craig R; Nguyen A; Udager AM; Wolfman DJ
Radiographics; 2021; 41(5):1408-1419. PubMed ID: 34388049
[TBL] [Abstract][Full Text] [Related]
43. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Utility of EMA, Vimentin and CD117 Immunohistochemical Markers in Subtyping Renal Cell Carcinoma in a Nigerian Tertiary Hospital: A 10-year Retrospective Study.
Nwadiokwu JI; Adegoke OO; Ajani MA; Okolo CA; Awosusi BL; Okebalama VC
West Afr J Med; 2023 Oct; 40(10):1035-1040. PubMed ID: 37906498
[TBL] [Abstract][Full Text] [Related]
45. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive review of chromophobe renal cell carcinoma.
Garje R; Elhag D; Yasin HA; Acharya L; Vaena D; Dahmoush L
Crit Rev Oncol Hematol; 2021 Apr; 160():103287. PubMed ID: 33753250
[TBL] [Abstract][Full Text] [Related]
47. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.
Erlmeier M; Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
BMC Urol; 2023 May; 23(1):90. PubMed ID: 37170275
[TBL] [Abstract][Full Text] [Related]
49. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.
Wang HY; Mills SE
Am J Surg Pathol; 2005 May; 29(5):640-6. PubMed ID: 15832088
[TBL] [Abstract][Full Text] [Related]
50. Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma: A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.
Liu Q; Cornejo KM; Cheng L; Hutchinson L; Wang M; Zhang S; Tomaszewicz K; Cosar EF; Woda BA; Jiang Z
Am J Pathol; 2018 Apr; 188(4):846-852. PubMed ID: 29353061
[TBL] [Abstract][Full Text] [Related]
51. Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype.
Ohashi R; Schraml P; Angori S; Batavia AA; Rupp NJ; Ohe C; Otsuki Y; Kawasaki T; Kobayashi H; Kobayashi K; Miyazaki T; Shibuya H; Usuda H; Umezu H; Fujishima F; Furusato B; Osakabe M; Sugai T; Kuroda N; Tsuzuki T; Nagashima Y; Ajioka Y; Moch H
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623347
[TBL] [Abstract][Full Text] [Related]
52. [Clinicopathological features and differential diagnosis of eosionphilic chromophobe renal cell carcinoma].
Zhang W; Song TT; He B; Wang H; Kang EH; Yu WJ; Zhong DC; Jiang YX; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2020 Dec; 49(12):1242-1248. PubMed ID: 33287507
[No Abstract] [Full Text] [Related]
53. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
Lüders C; Kristiansen G
Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
[TBL] [Abstract][Full Text] [Related]
54. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
55. Rhabdoid differentiation of chromophobe renal cell carcinoma.
Shannon BA; Cohen RJ
Pathology; 2003 Jun; 35(3):228-30. PubMed ID: 14506967
[TBL] [Abstract][Full Text] [Related]
56. Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma.
Krüger S; Sotlar K; Kausch I; Horny HP
Oncology; 2005; 68(2-3):269-75. PubMed ID: 16015044
[TBL] [Abstract][Full Text] [Related]
57. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance.
Velickovic M; Delahunt B; Störkel S; Grebem SK
Cancer Res; 2001 Jun; 61(12):4815-9. PubMed ID: 11406557
[TBL] [Abstract][Full Text] [Related]
58. CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers.
Yasir S; Herrera L; Gomez-Fernandez C; Reis IM; Umar S; Leveillee R; Kava B; Jorda M
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):454-61. PubMed ID: 22417859
[TBL] [Abstract][Full Text] [Related]
59. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
60. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
